Showing 1101-1110 of 1378 results for "".
- Dr. Michael H. Gold Joins AIVITA Scientific Advisory Boardhttps://practicaldermatology.com/news/dr-michael-h-gold-joins-aivita-scientific-advisory-board/2458042/Nashville dermatologist Michael H. Gold, MD, has joined AIVITA Biomedical’s Scientific Advisory Board. His addition comes as AIVITA prepares to launch its upcoming ROOT OF SKINTM line of rejuvenating skincare products. Dr. Gold,
- New Label Reflects Sustained Response for Sun Pharma's Odomzo in BCChttps://practicaldermatology.com/news/new-label-reflects-sustained-response-for-sun-pharmas-odomzo-in-bcc/2458045/Sun Pharma’s new Odomzo® (Sonidegib) label incorporates long-term data showing sustained duration of response of 26 months in treatment of locally advanced basal cell carcinoma. Odomzo® is an oral hedgehog inhibitor indicated for t
- Vanda's Tradipitant Improves Itch and Disease Severity in AD Patientshttps://practicaldermatology.com/news/vandas-tradipitant-improves-itch-and-disease-severity-in-ad-patients/2458053/Vanda Pharmaceuticals Inc.’s tradipitant improved the intensity of the worst itch patients experienced, as well as atopic dermatitis (AD) disease severity, according to results from an eight-week randomized Phase 2 clinical. Tradipitant
- FDA Accepts NDAs for Review of Binimetinib And Encorafenib for Advanced BRAF-mutant Melanomahttps://practicaldermatology.com/news/fda-accepts-ndas-for-review-of-binimetinib-and-encorafenib-for-advanced-braf-mutant-melanoma/2458058/The FDA has accepted Array BioPharma's New Drug Applications (NDAs) to support use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily (COMBO450) for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The FDA se
- FDA Approves T.R.U.E. Test Ready-To-Use Patch Test for Pediatric Usehttps://practicaldermatology.com/news/fda-approves-true-test-ready-to-use-patch-test-for-pediatric-use/2458057/The FDA has approved SmartPractice's T.R.U.E. TEST (truetest.com) ready-to-use patch test panels for pediatric patients as young as 6 years of age. T.R.U.E. TEST is the only FDA-approved product for diagnosing allergic contact derm
- Cemiplimab Receives FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinomahttps://practicaldermatology.com/news/cemiplimab-receives-fda-breakthrough-therapy-designation-for-advanced-cutaneous-squamous-cell-carcinoma/2458063/The FDA has granted Breakthrough Therapy designation status to Regeneron Pharmaceuticals, Inc. and Sanofi's cemiplimab (REGN2810) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) and adults with locally advanced and unresectable CSCC. Cemiplimab is an
- Galderma Names New Managers of Prescription Business and Aesthetic & Corrective Business Units; Dr. Kelly Huang to Obalonhttps://practicaldermatology.com/news/alisa-lask-to-oversee-galdermas-aesthetic-corrective-business-unit-dr-kelly-huang-to-obalon/2458064/Galdmera has named new managers of its Prescription Business and Aesthetic & Corrective Business units in the United States. Chris Chapman is Galderma’s new Vice President and General Manager of Prescription Business and Alisa Lask <
- Power Couple: Stroll Health Teams Up With First Dermhttps://practicaldermatology.com/news/power-couple-stoll-health-teams-up-with-first-derm/2458085/Stroll Health and First Derm are partnering to make dermatology care more accessible and available at a fair price. Stroll's health care 
- Bonti's Novel Gateway Neuromodulator Performs Well in Phase 2A Studyhttps://practicaldermatology.com/news/bontis-novel-serotype-e-botulinum-toxin-performs-well-in-phase-2a-study/2458094/Bonti’s lead product candidate, EB- 001, passed muster in a Phase 2A study for the treatment of glabellar lines. EB-001 is a novel serotype E botulinum neurotoxin with a unique efficacy profile, characterized by fast onset of action (about 24 hours
- Valeant's Newly Minted Ortho Dermatologic Unit Makes Big Splash at Summer AADhttps://practicaldermatology.com/news/valeants-newly-minted-orthodermatologic-division-makes-a-big-splash-at-summer-aad/2458105/It’s go big or go home for the newly re-branded Valeant Ortho Dermatologic division. At the 2017 American Academy of Dermatology in New York City, the company will officially launch Siliq (brodalumab) for psoriasis and announce their new name change. Dermwire